PhRMA wins one in California

Share this article:
The Pharmaceutical Research and Manufacturers of America won a victory in last night's elections with the defeat of California Proposition 79, which would have imposed price controls on manufacturers participating in the state's Medi-Cal program and allowed individuals to sue companies for profiteering.
A rival ballot measure, the PhRMA-sponsored Proposition 78, was also voted down, 58-41 percent. PhRMA spent $72 million on an advertising, PR and direct-mail blitz to defeat Proposition 79, which lost by a margin of 61-38 percent. Backed by unions and consumer activists, the measure would have required drug companies to offer steep discounts to the uninsured in order to participate in Medi-Cal. By contrast, Proposition 78 would have encouraged companies to offer discounts voluntarily.
PhRMA's outlay on the campaign included $50 million in media spend and $13 million on glossy mailers, according to California press.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...